Company news

iBio, Inc. news in 2026

iBio, Inc.'s news releases, calls and decks from 2026, newest first.

View company

iBio to Participate in Upcoming Investor Conferences

November 2, 2026

iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy

October 13, 2026

Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)

September 16, 2026

iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference

September 1, 2026

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

August 28, 2026

IntraBio’s Pivotal Phase III Trial in CACNA1A-Related Disorders Is Enrolling and Is Expected to Be Over-Enrolled and Complete Recruitment in October

August 19, 2026

iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer

August 4, 2026

IntraBio Announces Submission of Variation Application to the European Medicines Agency for AQNEURSA® for Ataxia-Telangiectasia

June 5, 2026

iBio to Participate in Upcoming Healthcare Investor Conferences

June 2, 2026

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

June 2, 2026

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

May 12, 2026

iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors

May 8, 2026

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

April 7, 2026

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

March 16, 2026

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

March 9, 2026

iBio to Participate in Upcoming Investor Conferences

February 24, 2026

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

February 9, 2026

iBio Announces $26 Million Private Placement

January 8, 2026

Decks in 2026